Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open-label, Phase I Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Recurrent or Metastatic Prostate Cancer

NCT07236112 is registered in ClinicalTrials.gov with C Ray Therapeutics as lead sponsor.

NCT NCT07236112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07236112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open-label, Phase I Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Recurrent or Metastatic Prostate Cancer
Lead sponsor
C Ray Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 8, 2026
Completion date
July 31, 2026
Enrollment
6 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer